carboplatin - Generic mfg.
Pluvicto (lutetium Lu 177 vipivotide tetraxetan) - Novartis
cabazitaxel - Generic mfg.
Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer (clinicaltrials.gov) - Oct 3, 2026 - P2 | N=44 | Recruiting | Sponsor: Case Comprehensive Cancer Center | Trial completion date: Dec 2026 ➔ Dec 2029 | Trial primary completion date: Dec 2026 ➔ Feb 2028 
Trial completion date • Trial primary completion date • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor • PTEN • TP53
http://clinicaltrials.gov/ct2/show/NCT06738303
 
Oct 3, 2026
 
Prev Next